Leerink Partners Reiterates Buy Rating on Quince Therapeutics
Leerink Partners has reaffirmed its buy rating on Quince Therapeutics with a $4 price target, a 323.73% upside from the current price.
Key Points
- Leerink Partners reiterated its buy rating on Quince Therapeutics with a $4 price target on June 24, 2026.
- Leerink Partners's $4 price target implies 323.73% upside from Quince Therapeutics, Inc.'s ($QNCX) current $0.94 share price.
- Shares of Quince Therapeutics traded at $0.97 on Wednesday, with a market cap of about $18.1 million.
- Insider activity shows recent buying by executives, while analysts maintain a positive outlook with a consensus buy rating.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, Leerink Partners reiterated its buy rating on Quince Therapeutics, Inc. (NasdaqGS:QNCX). Analyst Joseph Schwartz set a price target of $4, reaffirming confidence in the biotechnology company's prospects.
Leerink Partners vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Quince Therapeutics, Inc. Stock Down 97.2%
Shares of NasdaqGS:QNCX traded near $0.97 on Wednesday. Quince Therapeutics, with a market cap of approximately $18.1 million, operates in the biotechnology sector and has a beta of 1.373. The stock's 52-week range is between $0.79 and $45.50, with a 50-day moving average of $1.17 and a 200-day moving average of $13.04. The company currently has a negative forward P/E ratio as it isn't profitable, with a current ratio of 2.917 and a quick ratio of 2.819.
$QNCX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Quince Therapeutics, Inc.
Recent insider activity at Quince Therapeutics includes purchases by Christopher Senner and David Lamond, each acquiring 2,700 shares on June 11, 2026. Brigette Roberts, the Chief Corporate Affairs Officer, significantly increased her stake by acquiring 9,860,843 shares on May 18, 2026. Meanwhile, Brendan Hannah, CBO, COO & CCO, sold 365,000 shares on January 23, 2026, and Charles Ryan, the President, bought 200,000 shares on the same day.
Analysts Set New Price Targets
On June 24, 2026, Leerink Partners initiated a buy rating on Quince Therapeutics with a $4 price target. The day before, Cantor Fitzgerald also initiated coverage with a buy rating and the same target. D. Boral Capital maintained its buy rating with a $5 target back in January 2026. The overall analyst consensus remains positive, with a strong buy recommendation based on one analyst opinion.
About Quince Therapeutics
Quince Therapeutics, Inc., headquartered in South San Francisco, California, is a biotechnology company focused on developing treatments for rare and debilitating diseases. The company's lead asset, eDSP, is in Phase 3 trials for a rare pediatric neurodegenerative disease. Quince also utilizes its AIDE technology platform, which involves encapsulating drugs into red blood cells. Dr. Dirk Thye, M.D., leads the company as CEO, and it employs 38 people.
Bottom Line
Leerink Partners' reiteration of a buy rating with a $4 target reflects continued optimism about Quince Therapeutics' future. Investors keep an eye on such analyst ratings for insights into potential stock performance. As always, it's important to remember that analyst ratings and 13F filings provide a backward-looking view and may not reflect current positions or market conditions.
Get Quince Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $QNCX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.